Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH375 vs Chemotherapy in Previously Treated KRAS G12D-Mutant Metastatic Pancreatic Cancer
NCT07262567Phase 3Recruiting
- Sponsor
- GenFleet Therapeutics
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of GFH375 in pancreatic cancer (PC), sponsored by GenFleet Therapeutics. Started Dec 2025; status: recruiting.
02
Drugs
GFH375
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07262567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07262567.